DK2268282T3 - Flydende formulering af deferipron med behagelig smag - Google Patents
Flydende formulering af deferipron med behagelig smag Download PDFInfo
- Publication number
- DK2268282T3 DK2268282T3 DK08748186.7T DK08748186T DK2268282T3 DK 2268282 T3 DK2268282 T3 DK 2268282T3 DK 08748186 T DK08748186 T DK 08748186T DK 2268282 T3 DK2268282 T3 DK 2268282T3
- Authority
- DK
- Denmark
- Prior art keywords
- formulation
- approx
- per liter
- grams
- deferiprone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Oral, farmaceutisk, flydende formulering, omfattende deferipron i en mængde på mellem ca. 20 og ca. 200 gram per liter af formuleringen og en smagsmaskeringsammensætning, hvor smagsmaskeringsammensætning omfatter en virksom mængde af et sødemiddel per liter af flydende formulering, hvor sødemidlet er udvalgt fra gruppen bestående af aspartam, saccharin, saccharin-natrium, sucralose og blandinger deraf, en virksom mængde af fortykkelses- og suspensionsmiddel per liter af flydende formulering, hvor fortykkelses- og suspensionsmidlet er hydroxyethyl-cellulose, og hvor mængden af hydroxyethylcellulose ligger mellem ca. 0,5 og ca. 3 gram per liter af formuleringen, en virksom mængde af et fugtighedsbevarende stof per liter af flydende formulering, hvor det fugtighedsbevarende stof er glycerin, og hvor mængden af glycerin ligger mellem ca. 100 og ca. 900 gram per liter af formuleringen, og en virksom mængde af mindst ét smagsstof, hvor smagsstoffet er udvalgt fra gruppen bestående af naturlige smagsstoffer, naturlige frugtsmagsstoffer, kunstige smagsstoffer, kunstige frugtsmagsstoffer, pebermynte, pebermynteolier og blandinger deraf, hvor en endelig form af den orale, flydende, farmaceutiske formulering har en i det væsentlige ikke-bitter og behagelig smag.
2. Formulering ifølge krav 1, hvor smagsstoffet er udvalgt fra gruppen bestående af kirsebær, druer, jordbær, blodappelsin, melon, banan og citronvanilje og blandinger deraf.
3. Formulering ifølge krav 1, omfattende mere end et smagsstof.
4. Formulering ifølge krav 1, hvor sødemidlet er sucralose.
5. Formulering ifølge krav 4, hvor sucralose foreligger i en mængde på mellem ca. 5 gram og ca. 30 gram per liter af formuleringen.
6. Formulering ifølge krav 1, hvor den flydende, farmaceutiske formulering har en pFI-værdi på mellem ca. 2,5 og ca. 5,0.
7. Formulering ifølge krav 6, yderligere omfattende koncentreret saltsyre.
8. Formulering ifølge krav 1, hvor sødemidlet er udvalgt fra gruppen bestående af de højintensive, kunstige sødemidler aspartam, sucralose og saccharin.
9. Formulering ifølge krav 1, hvor sødemidlet foreligger i en mængde på mellem ca. 0,1 og ca. 3 vægtprocent.
10. Formulering ifølge krav 1, hvor deferipron foreligger i en mængde på mellem ca. 50 gram og ca. 200 gram per liter af formuleringen.
11. Formulering ifølge krav 2, hvor smagsstoffet omfatter kunstig kirsebærsmag.
12. Formulering ifølge krav 11, hvor pebermynteolie tilsættes som et yderligere smagsstof.
13. Behagelig, flydende, farmaceutisk formulering ifølge krav 1, omfattende: ca. 50-200 gram deferipron per liter af formuleringen, ca. 15 gram sucralose per liter af formuleringen, ca. 500 gram glycerin per liter af formuleringen, ca. 1 gram hydroxyethylcellulose per liter af formuleringen, ca. 59 gram koncentreret saltsyre per liter af formuleringen, ca. 0,40 gram FD&C Yellow No. 6 per liter af formuleringen, ca. 2 gram kunstig kirsebærsmag per liter af formuleringen, ca. 0,10 gram pebermynteolie per liter af formuleringen og en tilstrækkelig mængde af renset vand for at give 1 liter af formuleringen.
14. Formulering ifølge et af kravene 1 til 13, hvor formuleringen er til anvendelse i behandling af jernoverbelastningstilstande af hjertet, mitokondrie eller centralnervesystemet, herunder hjernen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2008/000784 WO2009129592A1 (en) | 2008-04-25 | 2008-04-25 | Liquid formulation for deferiprone with palatable taste |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2268282T3 true DK2268282T3 (da) | 2014-11-24 |
Family
ID=41216357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08748186.7T DK2268282T3 (da) | 2008-04-25 | 2008-04-25 | Flydende formulering af deferipron med behagelig smag |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8703156B2 (da) |
| EP (1) | EP2268282B1 (da) |
| KR (1) | KR101490721B1 (da) |
| CN (1) | CN102014904B (da) |
| AP (1) | AP2010005454A0 (da) |
| AU (1) | AU2008355464C1 (da) |
| BR (1) | BRPI0822206B8 (da) |
| CA (1) | CA2722393A1 (da) |
| CR (1) | CR11744A (da) |
| CY (1) | CY1116146T1 (da) |
| DK (1) | DK2268282T3 (da) |
| EA (1) | EA022751B1 (da) |
| ES (1) | ES2539414T3 (da) |
| HK (1) | HK1152871A1 (da) |
| HR (1) | HRP20150083T1 (da) |
| IL (1) | IL208876A (da) |
| MX (1) | MX2010011701A (da) |
| NZ (1) | NZ588602A (da) |
| PL (1) | PL2268282T3 (da) |
| PT (1) | PT2268282E (da) |
| RS (1) | RS53689B1 (da) |
| SI (1) | SI2268282T1 (da) |
| UA (1) | UA102254C2 (da) |
| WO (1) | WO2009129592A1 (da) |
| ZA (1) | ZA201008374B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2246044A1 (en) * | 2009-04-21 | 2010-11-03 | Pierre Fabre Dermo-Cosmétique | Paediatric solutions comprising a beta-blocker |
| BR112012000079A2 (pt) | 2009-07-03 | 2017-07-25 | Apotex Tech Inc | derivados fluorados de 3-hidroxipiridin-4-onas |
| CA2885394A1 (en) | 2012-11-12 | 2014-05-15 | Cipla Limited | Fixed dose pharmaceutical composition comprising deferasirox and deferipone |
| US20190240144A1 (en) * | 2016-05-18 | 2019-08-08 | Khashayar Karimian | Effervescent deferiprone tablet |
| GR1009462B (el) * | 2017-10-05 | 2019-02-15 | Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. | Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση |
| CA3077514C (en) | 2017-10-25 | 2022-10-11 | Chiesi Farmaceutici S.P.A. | Delayed release deferiprone tablets and methods of using the same |
| BR112021017954A2 (pt) * | 2019-03-14 | 2021-11-16 | Neuroenergy Ventures Inc | Formulação de mascaramento de sabor para compostos de corpo cetônico |
| US12053447B2 (en) | 2019-06-25 | 2024-08-06 | NuBioPharma, LLC | Oral solution and powder to liquid compositions of balsalazide |
| NL2024161B1 (en) * | 2019-11-05 | 2021-07-20 | Mperium B V | Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| WO2024023785A1 (en) | 2022-07-29 | 2024-02-01 | Berlia Sushma Paul | A stable pharmaceutical oral liquid formulation of an antispasmodic agent |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2918402A (en) | 1958-07-29 | 1959-12-22 | Dodge Chem Co | Bactericidal-fungicidal compositions |
| NL300788A (da) | 1962-12-20 | |||
| CA1095921A (en) | 1976-08-02 | 1981-02-17 | Thomas M. Brennan | Preparation of gamma-pyrones |
| GB8308055D0 (en) | 1983-03-24 | 1983-05-05 | Hider R C | Pharmaceutical compositions |
| GB8308054D0 (en) | 1983-03-24 | 1983-05-05 | Hider R C | Pharmaceutical compositions |
| USRE34313E (en) | 1983-09-23 | 1993-07-13 | National Research Development Corporation | Pharmaceutical compositions |
| GB8325496D0 (en) | 1983-09-23 | 1983-10-26 | Hider R C | Pharmaceutical compositions |
| GB8329043D0 (en) | 1983-10-31 | 1983-11-30 | Hider R C | Pharmaceutical compositions |
| JPH01305081A (ja) | 1988-04-04 | 1989-12-08 | E R Squibb & Sons Inc | ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類 |
| DE3826846A1 (de) | 1988-08-06 | 1990-02-08 | Goedecke Ag | Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| JPH0714872B2 (ja) | 1990-02-06 | 1995-02-22 | 昭和薬品化工株式会社 | シロップ剤組成物 |
| GB9100465D0 (en) | 1991-01-09 | 1991-02-20 | Hider Robert C | Pharmaceutical compositions |
| US5624807A (en) | 1992-07-22 | 1997-04-29 | The Mclean Hospital Corporation | Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms |
| EP0620001A1 (en) | 1993-04-16 | 1994-10-19 | McNEIL-PPC, INC. | Aqueous pharmaceutical suspension and process for preparation thereof |
| EP0741717A1 (en) | 1994-01-31 | 1996-11-13 | Cultor Ltd. | Method of synthesizing gamma pyrones |
| JP2001508755A (ja) | 1994-04-08 | 2001-07-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | 哺乳動物でラジカルダメージを減少させるために鉄キレート化合物を用いる方法 |
| CA2172807C (en) | 1994-08-01 | 1999-10-12 | Keith S. Lienhop | Tastemasked liquid pharmaceutical delivery system |
| US5616621A (en) | 1995-01-30 | 1997-04-01 | American Home Products Corporation | Taste masking liquids |
| JPH0925234A (ja) | 1995-07-12 | 1997-01-28 | Wakunaga Pharmaceut Co Ltd | 脳疾患改善剤 |
| US5763449A (en) | 1996-08-07 | 1998-06-09 | Ascent Pediatrics, Inc. | Pleasant-tasting aqueous liquid composition of a bitter-tasting drug |
| GB9711093D0 (en) | 1997-05-29 | 1997-07-23 | British Tech Group | Novel orally active iron (III) chelators |
| KR100801236B1 (ko) | 1998-08-28 | 2008-02-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고미 등을 경감한 의약조성물 |
| US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| US6133322A (en) | 1998-10-29 | 2000-10-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
| US6933104B1 (en) | 1999-04-23 | 2005-08-23 | Shiva Biomedical, Llc | Diagnosis and treatment of human kidney diseases |
| IL130324A0 (en) | 1999-06-07 | 2000-06-01 | Yeda Res & Dev | Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators |
| AUPQ262499A0 (en) | 1999-09-02 | 1999-09-23 | University Of Queensland, The | Novel iron chelators |
| CA2313270C (en) | 2000-06-30 | 2011-09-13 | Apotex Inc. | Use of deferiprone in treating and preventing iron-induced cardiac disease |
| BR0207930A (pt) | 2001-03-05 | 2004-03-02 | Ortho Mcneil Pharm Inc | Composições farmacêuticas lìquidas com sabor mascarado |
| AU2003222513A1 (en) | 2002-03-08 | 2003-09-22 | Protemix Corporation Limited | Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure |
| CA2478411C (en) * | 2002-03-12 | 2010-09-28 | Bristol-Myers Squibb Company | Palatable oral suspension and method |
| US20040101521A1 (en) | 2002-07-12 | 2004-05-27 | The Buck Institute For Research On Aging | Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression |
| CA2505476C (en) | 2002-11-07 | 2015-05-26 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| DE10336497B4 (de) | 2003-08-08 | 2007-04-05 | Freie Universität Berlin | Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen |
| KR20070009671A (ko) * | 2004-05-06 | 2007-01-18 | 사이덱스 인크 | 세르트랄린 및 술포알킬 에테르 시클로덱스트린을 함유하는맛 마스킹된 제제 |
| JP2008500347A (ja) | 2004-05-24 | 2008-01-10 | ニュー・ヨーク・ユニヴァーシティー | 高血糖症による血糖の急激な増加及び／又は急激な遊離脂肪酸流動の増加の病理学的影響の治療方法又は予防方法 |
| US9737511B2 (en) | 2004-05-24 | 2017-08-22 | Geoffrey C. GURTNER | Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux |
| US7728038B2 (en) | 2004-08-04 | 2010-06-01 | University Of Utah Research Foundation | Methods for chelation therapy |
| US20060093630A1 (en) | 2004-10-29 | 2006-05-04 | Buehler Gail K | Dye-free pharmaceutical suspensions and related methods |
| US20070197469A1 (en) | 2006-02-17 | 2007-08-23 | Murthy Yerramilli V | Fluoroquinolone carboxylic acid salt compositions |
| DK1991225T3 (da) | 2006-02-22 | 2013-12-16 | Apotex Technologies Inc | Anvendelse af deferipron og fremgangsmåder til at behandle og/eller forebygge Friedreichs ataksi, der resulterer af intracellulær fejlhåndtering af jern |
| CA2627529A1 (en) | 2007-03-28 | 2008-09-28 | Apotex Technologies Inc. | Fluorinated derivatives of deferiprone |
| GB0803019D0 (en) | 2008-02-19 | 2008-03-26 | Btg Int Ltd | Fluorinated compounds |
-
2008
- 2008-04-25 SI SI200831334T patent/SI2268282T1/sl unknown
- 2008-04-25 DK DK08748186.7T patent/DK2268282T3/da active
- 2008-04-25 EP EP08748186.7A patent/EP2268282B1/en active Active
- 2008-04-25 EA EA201071235A patent/EA022751B1/ru not_active IP Right Cessation
- 2008-04-25 KR KR1020107026479A patent/KR101490721B1/ko active IP Right Grant
- 2008-04-25 RS RS20140661A patent/RS53689B1/en unknown
- 2008-04-25 UA UAA201013859A patent/UA102254C2/ru unknown
- 2008-04-25 AU AU2008355464A patent/AU2008355464C1/en active Active
- 2008-04-25 PT PT87481867T patent/PT2268282E/pt unknown
- 2008-04-25 CA CA2722393A patent/CA2722393A1/en not_active Abandoned
- 2008-04-25 MX MX2010011701A patent/MX2010011701A/es active IP Right Grant
- 2008-04-25 AP AP2010005454A patent/AP2010005454A0/xx unknown
- 2008-04-25 CN CN2008801288682A patent/CN102014904B/zh active Active
- 2008-04-25 BR BRPI0822206A patent/BRPI0822206B8/pt active IP Right Grant
- 2008-04-25 US US12/989,127 patent/US8703156B2/en active Active
- 2008-04-25 WO PCT/CA2008/000784 patent/WO2009129592A1/en active Application Filing
- 2008-04-25 PL PL08748186T patent/PL2268282T3/pl unknown
- 2008-04-25 ES ES08748186.7T patent/ES2539414T3/es active Active
- 2008-04-25 NZ NZ588602A patent/NZ588602A/xx unknown
-
2010
- 2010-10-20 CR CR11744A patent/CR11744A/es not_active Application Discontinuation
- 2010-10-21 IL IL208876A patent/IL208876A/en active IP Right Grant
- 2010-11-23 ZA ZA2010/08374A patent/ZA201008374B/en unknown
-
2011
- 2011-07-05 HK HK11106935.2A patent/HK1152871A1/xx unknown
-
2015
- 2015-01-22 HR HRP20150083AT patent/HRP20150083T1/hr unknown
- 2015-01-26 CY CY20151100079T patent/CY1116146T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2268282T3 (da) | Flydende formulering af deferipron med behagelig smag | |
| US6806256B2 (en) | Taste masked liquid pharmaceutical compositions | |
| JP2874967B2 (ja) | 本質的に水に不溶な薬剤活性体のための薬剤水懸濁液 | |
| JP3778518B2 (ja) | 苦味薬剤の味の良い水性液体組成物 | |
| US20060024335A1 (en) | Oral compositions which mask the bitter taste of a bitter-tasting agent | |
| US9040089B2 (en) | Oral compositions of clindamycin | |
| JP6410814B2 (ja) | フェキソフェナジンを含む経口投与用液体医薬組成物 | |
| US10959985B1 (en) | Pharmaceutical compositions including carvedilol and methods of using the same | |
| EP3968955A1 (en) | Pharmaceutical oral liquid solution of ivacaftor | |
| SG190579A1 (en) | Liquid formulation for deferiprone with palatable taste | |
| NL2024160B1 (en) | Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition | |
| WO2024116198A1 (en) | Oral liquid formulation of empagliflozin or its pharmaceutically acceptable salt thereof | |
| EP4279062A1 (en) | Liquid composition and its use, treatment method and kit | |
| WO2024144482A1 (en) | Pharmaceutical oral suspension compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients | |
| US20240091217A1 (en) | Stable pharmaceutical oral liquid formulation of an antispasmodic agent | |
| WO2021130684A1 (en) | Orally dissolving formulations of prucalopride |